Sofwave™ Gains Additional U.S. Patent Protection For the Company’s Proprietary SUPERB™ Technology
SAN CLEMENTE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, announced the allowance of a second patent by the U.S. Patent and Trademark Office. The allowance grants additional U.S. patent protection for key feature sets of the Company’s proprietary SUPERB™ (“Synchronous Ultrasound Parallel Beam”) technology.
- The allowance grants additional U.S. patent protection for key feature sets of the Company’s proprietary SUPERB™ (“Synchronous Ultrasound Parallel Beam”) technology.
- “This second U.S. patent allowance further ensures IP protection of the underlying proprietary design, innovation and configuration of SUPERB™,” said Louis Scafuri, CEO of Sofwave Medical.
- “The key elements covered under this patent include our device’s heating and cooling array.
- The Company has an additional 31 patents pending globally and continues to focus on further building the IP around its transformative technology.